The Expression of Galectin-1 in Melanocytic Nevus, Dysplastic Nevus and Malignant Melanoma.
- Author:
Seong Min KIM
1
;
Tae Jin YOON
Author Information
1. Department of Dermatology, School of Medicine, Gyeongsang National University, Jinju, Korea.
- Publication Type:Original Article
- Keywords:
Dysplastic nevus;
Galectin-1;
Maligant melanoma;
Melanocytic nevus
- MeSH:
Benzamides;
Cell Transformation, Neoplastic;
Dysplastic Nevus Syndrome;
Galectin 1;
Galectins;
Humans;
Melanoma;
Neoplasm Metastasis;
Nevus, Intradermal;
Nevus, Pigmented;
Proteins;
Tyrosine
- From:Korean Journal of Dermatology
2009;47(9):989-996
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Galectin-1 (Gal-1) is a member of the galectin family of proteins, which are carbohydrate-binding proteins with an affinity for beta-galactosides. Gal-1 is differentially expressed by various normal and pathological tissues and it performs polyvalent, wide-ranging biological activities. A Gal-1 expression or over-expression in tumors and/or in the tissue surrounding them must be considered as a sign of malignant tumor progression that is often related to tumor metastasis. Although Gal-1 also plays important roles for tumorigenesis and tumor progression, the expression of Gal-1 in melanocytic nevus, dysplastic nevus and malgant melanoma has not yet been investigated. OBJECTIVE: We wanted to investigate and compare the expression of Gal-1 in melanocytic nevus, dysplastic nevusand malignant melanoma. METHODS: The paraffin-embedded specimens of 9 cases of malignant melanoma (MM), 6 cases of dysplastic nevus (DN) and 6 cases of intradermal nevus (IN) were subjected to immunohistochemical staining for Gal-1. RESULTS: The percentage of positive cells for Gal-1 in the MM was significantly higher than that of the DN and IN (p<0.01). The staining intensity of the positive cells for Gal-1 was the highest also in the MM. Meanwhile Gal-1 was more strongly expressed in highly atypical (more pleomorphic, more atypical mitoses) areas of the melanoma tissues. But there was no significant difference between the DN and IN for the expression of Gal-1. LIMITATION: This study is restricted to a small number of patients. CONCLUSION: The present study suggests that Gal-1 is more strongly expressed in malignant melanoma than in melanocytic nevus and dysplastic nevus. Interestingly, Gal-1 was more strongly expressed in the highly atypical portions of the melanoma tissue. Gal-1 might well contribute to the tumorigenesis and malignancy of melanocytes.
